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A B S T R A C T
The aim of this study was to evaluate the effects of extraocular muscle injection of botulinum toxin-A (BTX-A) on
intraocular pressure (IOP) and proptosis in patients with ocular motility disturbances in thyroid associated orbitopathy
(TAO). In 17 patients (20 eyes) with restrictive strabismus and diplopia, BTX -A injections were applied. Intraocular
pressure was measured with a Goldmann applanation tonometer in primary gaze position before and 2–4 weeks after
BTX-A injection. Extraorbital prominention of the eyeball was measured before and after BTX -A injection using a
Hertel instrument. Before the injection, the mean IOP in primary position of gaze was 18.6± 2.8 mmHg and 2–4 weeks af-
ter BTX-A injection was 16.9±3.3 mmH; (p=0.001). There was no statistically significant difference in Hertel egzoph-
thalmometer readings before and after BTX-A injection, 21.5±2.7 mm vs 22.0± 2.6 mm; (p=0.678). In conclusion, BTX-A
injection has a secondary lowering effect on IOP in TAO due to relaxation of extraocular muscles, but with no influence
on proptosis.
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Introduction
The thyroid associated orbitopathy (TAO) is charac-
terized by proptosis and extraocular muscle involvement
which can cause restrictive strabismus and increased
intraocular pressure (IOP)1.Causes of elevated IOP in
patients with TAO have been reported to be associated
with the mechanical effect of extraocular thickening, ele-
vated episcleral venus pressure, pressure of swollen or-
bital tissues, accumulation of mucopolysaccharide in the
trabecular meshwork and finally coexistent open angle
glaucoma2–7.
Elevated IOP in up gaze is a common finding and is
explained by a tight inferior rectus muscle that blocks
the episcleral equeous outflow and orbital congestion2,8.
It was found that in the Graves disease of recent unset,
the raised muscle tension and reduced elasticity of the af-
fected muscles, and hence strabismus, were caused pri-
marily by active muscle contraction, not by fibrosis9.
Treatment with botulinum toxin-A (BTX) in TAO has
been shown previously10–13. In a small retrospective se-
ries of cases BTX-A caused decreased IOP on restrictive
strabismus associated with thyroid-related orbitopathy7.
The aim of this study was to assess the effects of
BTX-A on IOP and proptosis in patients with TAO and
related restrictive strabismus in observational case-study.
Material and Methods
We retrospectively studied the records of 17 patients
(20 eyes, 14 female aged 49.9, range, 40–61 years and 3
male aged 50.4, range, 50–57 years, with TAO and re-
lated restrictive strabismus or diplopia treated at the De-
partment of Ophthalmology University Hospital Split
during the period from January 2004 to December 2006.
Patient data are shown in Table 1.
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Before the therapy two patients were euthyroid and
the others were hyperthyroid. In the time of therapy they
were either euthyroid or with a stable hormonal status of
the thyroid gland under medication for at least two
months.
Considering the time of initial complaints and the
unset of the thyroid gland disease, 5 patients simulta-
neously developed symptoms of the thyroid and eye dis-
ease. Twelve patients developed eye symptoms after the
unset of the thyroid gland disease.
There were twelve active smokers. The median time
of duration of the eye signs of TAO was 11 months,
ranged 9–15 months.
All patients had a history of TAO based on the pres-
ence of typical clinical ophthalmic findings (eyelid retrac-
tion, limitation of ocular motility, strabismus, proptosis
and computed tomography (CT) that revealed evidence
of extraocular muscle enlargement). All the patients
were with active TAO and according to CAS score were
with CAS 4 and more. Seven eyes were with CAS 4 and 5
and 13 eyes with CAS 6 and 7.
Botulinum toxin-A (Botox-Allergan) is a vial of 100
units of the medication in the form of crystal powder
which is dissolved with 1.0 ml 0.9% solution of natrium
chloride so that 0.1 ml of the solution consists 10 IU of
Botulinum toxin A. 0.2 ml (20 IU) were applied with an
insulin syringe under topical anesthesia in the site of the
inferior rectus muscle of the affected side.
None of the patients was taking antiglaucoma medi-
cations, glucocorticoids or was treated with orbital ra-
diotherapy; only local supportive lubricants were used.
Examination of all patients included in the study was
performed before and 2–4 weeks after the treatment (vi-
sual acuity, inspection of the eyelids and cornea, ocular
motility measurement, Hess-Lancaster test, ophthal-
moscopy). Preinjection and postinjection IOP was mea-
sured by an unmasked physican using a Goldmann
aplanation tonometer in the primary position. Extra-
orbital prominention of the eyeball was measured using
a Hertel instrument.
Statistical analysis was performed using t-test, c²-test,
Mann-Whitney U-test, Wilcoxon test, Mc Nemar test and
descriptive statistics.
Results
IOP and proptosis measured by Hertel egzophthal-
mometry taken before and after the injection of BTX-A
are shown in Table 2.
Before the injection, the mean IOP was 18.6±2.8 mm
Hg (range, 12–22 mmHg). After 2–4 weeks following
BTX-A injection, the mean IOP was significantly decrea-
sed (16.9±3.3 mmHg, range 13–22 mmHg, p=0.001).The
decrease in IOP was maintained in seventeen eyes for
four weeks of the observed period of time. In three eyes
the slight increase of IOP (1–3 mm Hg) was noticed two
weeks following BTX-A injection and maintained in the
observed period of four weeks. After BTX-A injection 8 of
the eyes with CAS 6 and 7 reduced CAS score to 4 and 5
(61.5 %) (Mc Nemar test: p=0.008).
Using Wilcoxon test we did not find a statistically
significant difference in proptosis before and after
treatment with BTX-A; 21.5±2.7 mm vs 22.0±2.6 mm;
(p=0.678).
Discussion
In Graves’ disease increased IOP and proptosis are
the results of orbital tissue infiltration and active extra-
ocular muscle contraction13–14.
Increased IOP in TAO has been attributed to in-
creased episcleral venous pressure resulting from orbital
congestion and venous outflow obstruction, increased re-
sistance of trabecular outflow, restriction and compres-
sion of the globe by fibrotic and enlarged rectus muscles,
a genetically linked predisposition to glaucoma, or in-
creased mucopolysaccharide deposition in the trabecular
meshwork16. In courses of Graves’ ophthalmopathy of re-
cent unset, raised muscle tension and reduced elasticity
of the affected muscles were caused primarily by active
muscle contraction, not by fibrosis13.
Kikkawa and associates reported a significant de-
crease in IOP following BTX injections7. The limitation
of their study was a small number of patients. In that
study only 5 patients were without treatment at the
time of BTX injection. The IOP measurements perfor-
med in our study were taken in primary gaze position.
We didn’t perform IOP measurements in up gaze posi-
tion neither in down gaze position because the aim of
















Duration of Disease 9–15
TABLE 2
INTRAOCULAR PRESSURE AND HERTEL




















the study was to define changes in IOP following BTX-A
injections, but not to determine ocular hypertension.
Ocular hypertension is defined only if IOP is increased
in all positions of gaze. We considered that IOP mea-
sured in primary position was sufficient to assess the ef-
fect of BTX-A injection on IOP. We speculate that the ef-
fect of BTX-A injection into the inferior rectus muscle
relieves the muscle contraction and in turn has a lower-
ing effect on IOP.
To the best of our knowledge this is the first study on
the effect of applied BTX-a injection on proptosis in re-
strictive myopathy related to TAO.
We didn’t find a significant difference in proptosis
measured by Hertel egzophthalmometry. This could be
explained solely by the effect of BTX-A on extraocular
muscle contraction but not on muscle augmentation.
In conclusion, this study clearly demonstrates that
BTX-A injections applied in patients with restrictive
myopathy related to TAO have a lowering effect on IOP
but without influence on proptosis.
The limitation of our study was a relatively small
number of patients and IOP measurements were not
performed in up gaze position which is probably more
sensitive.
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UTJECAJ LOKALNE PRIMJENE BOTULINUM TOKSINA-A NA INTRAOKULARNI TLAK I
PROPTOZU KOD TIROIDNE ORBITOPATIJE
S A @ E T A K
Cilj istra`ivanja je bio ispitati utjecaj injekcije Botulinum toksina-A (BTX-A) u podru~je ekstraokularnih mi{i}a na
intraokularni tlak (IOP) i proptozu u pacijenata sa poreme}ajima bulbomotorike u tiroidnoj orbitopatiji (TO). Injekcije
BTX-A primjenjene su u 17 pacijenata (20 o~iju) sa restriktivnim strabizmom i dvoslikama. Mjerenje IOT-a aplana-
cionom tonometrijom po Goldmannu na~injeno je u primarnom polo`aju oka prije i 2–4 tjedna nakon injekcije BTX-A.
Ekstraorbitalna prominencija o~ne jabu~ice mjerena je egzoftalmometrom po Hertelu prije i 2–4 tjedna poslije BTX-A
injekcije. Srednja vrijednost IOT-a prije injekcije u primarnom polo`aju oka bila je 18,6±2,8 mm Hg, a 2–4 tjedna poslije
BTX-A injekcije iznosila je 16,9±3,3 mm Hg; (p=0,001). Nije bilo statisti~ki zna~ajne razlike u vrijednosti egzoftal-
mometrije prije i nakon injekcije BTX-A, 21,5±2,7 mm prema 22,0±2,6 mm; (p=0,678). Zaklju~no, injekcija BTX-A ima
sekundarno djelovanje na sni`enje IOT-a u pacijenata sa TO zbog relaksacije ekstraokularnih mi{i}a, ali bez utjecaja na
proptozu.
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